The company sells biosensors which have already been sold to leading research facilities in Germany and Switzerland. Particularly in medical and pharmaceutical research, but also in diagnostics and the various biotechnology segments, such systems can identify a wide variety of substances and analyse their physical mechanisms with high precision and without the influence of disruptive marker molecules.
The funds will enable the company to commercialise the systems to the research market.
Commenting on the investment, Dr. Bernd Goergen, Senior Investment Manager at High-Tech Gründerfonds, said: “We are very pleased to be contributing with this finance to the faster development and broader marketing of a technology that has already been tried and tested by customers.
“The clear advantages of the SAW-based method versus competing products in the area of marker-free detection of molecular interaction hold out the prospect of a leading position in the research market. “Furthermore, they allow promising expansion of the business activity into numerous other markets as well”.